S. Ongoren Et Al. , "Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.," Hematology (Amsterdam, Netherlands) , vol.23, no.4, pp.212-220, 2018
Ongoren, S. Et Al. 2018. Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.. Hematology (Amsterdam, Netherlands) , vol.23, no.4 , 212-220.
Ongoren, S., Eskazan, A. E., Suzan, V., Savci, S., Ozunal, I. E., Berk, S., ... Yalniz, F. F.(2018). Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.. Hematology (Amsterdam, Netherlands) , vol.23, no.4, 212-220.
Ongoren, Seniz Et Al. "Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.," Hematology (Amsterdam, Netherlands) , vol.23, no.4, 212-220, 2018
Ongoren, Seniz Et Al. "Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.." Hematology (Amsterdam, Netherlands) , vol.23, no.4, pp.212-220, 2018
Ongoren, S. Et Al. (2018) . "Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.." Hematology (Amsterdam, Netherlands) , vol.23, no.4, pp.212-220.
@article{article, author={Seniz Ongoren Et Al. }, title={Third-line treatment with second-generation tyrosine kinase inhibitors (dasatinib or nilotinib) in patients with chronic myeloid leukemia after two prior TKIs: real-life data on a single center experience along with the review of the literature.}, journal={Hematology (Amsterdam, Netherlands)}, year=2018, pages={212-220} }